Written by MicroDok

Type I hypersensitivity which can also be called anaphylactic or atopic hypersensitivity reaction is an IgE-mediated type of allergy that occurs immediately following the exposure or prior sensitization of the host’s body by the invasion of an allergen. It generally occurs when an allergen binds to the surface of an IgE molecule whose FC region or receptor is attached to a mast cell or basophil; and this binding leads to the degranulation of the mast cells to release pharmacologically active substances (e.g. histamine and heparin) that causes adverse inflammatory reactions in the affected individuals. There is usually a short time observed between the exposure of a sensitized human host to an allergen and the appearance of clinical symptoms associated with anaphylactic reaction; and this is why Type I hypersensitivity is generally regarded as an immediate-type hypersensitivity reaction.

Mast cells are immune system cells that are derived from the bone marrow cells during haematopoiesis; and they are present in several tissues of the body (especially in connective tissues) where they bind to the FC region of IgE molecules to mediate inflammatory response as is obtainable in hypersensitivity reactions. They are cells that bind IgE; and the effector molecule of Type I hypersensitivity is IgE. Mast cells contain numerous cytoplasmic granules that are shed following the cross-linking of an IgE molecule with an allergen in a human or animal host; and they have receptors for the FC region of immunoglobulin E on their cells surfaces. Type I hypersensitivity is an immediate-type allergic reaction; and this type of hypersensitivity reaction can be localized or systemic/generalized inflammatory response depending on the antigenicity of the invading allergen(s) amongst other factors.

In Type I hypersensitivity reaction, the host becomes sensitized to a given allergen following an initial introduction of the antigen into the host’s body. The host’s immune system produces numerous IgE against the invading allergen at the first exposure to the antigen; and the IgE molecules produced becomes attached via their FC region to receptors on the mast cells or basophils. The IgE so produced parades the general circulation in search of allergens to bind to. After some days or months past the first exposure and the host becomes exposed to the same allergen the second time, the allergen cross-links the IgE molecules on the mast cells or basophils (i.e. the IgE attaches the allergen to the mast cells), and this result in the production of chemical or physiological or vasoactive mediators such as histamine and prostaglandins amongst others which causes an immediate anaphylactic reaction in the affected animal host (Figure 18). The degranulation of the mast cells or basophils during anaphylactic reaction is mainly mediated via the cross-linking of the IgE molecule(s).

Figure 18: Illustration of Type I hypersensitivity reaction. IgE is the main mediator of Type I hypersensitivity or anaphylactic reaction; and the main biological function of this immunoglobulin molecule in anaphylactic reaction is to cross-link (i.e. act as a bridge) between the allergen that invaded the body and the mast cells or basophils which are known to contain cytoplasmic granules (e.g. histamine). The FC region of the IgE molecules binds specifically to the receptors on the mast cells or basophils while its Fab region or fragment binds to the allergen; and this binding leads to the degranulation of the mast cells to release vasoactive substances such as histamine, heparin and prostaglandins amongst others which ultimately provoke the clinical or subclinical conditions associated with the Type I hypersensitivity reaction.

Diarrhea, urticaria, vomiting, eczema, body itching, asthma, hay fever, and food allergies are some examples of Type I hypersensitivity reaction. However, in severe or life-threatening anaphylactic reactions (e.g. disintegration of the vascular system) death can occur unless appropriate medical help is rendered to the affected human host. Type I hypersensitivity reaction is the commonest type of allergic reactions in humans. It is worthy of note that the physiological mediators produced in anaphylactic reactions also mediate a protective inflammatory reaction in the host, but in severe responses these mediators could cause harsh medical condition (i.e. anaphylactic reactions) in the host. The pharmacologically active substances released in Type I hypersensitivity reaction can also cause the vasodilation or constriction of smooth muscles; and this may affect the normal physiological functions of some vital muscular activities in the affected hosts especially in respiratory activities such as in asthma sufferers whose allergen entered the body via the respiratory tract by inhalation.

Allergens that provoke anaphylactic reaction can also enter the body via foods (i.e. by ingestion) and through direct inoculation or drug administration especially parenterally. Microbial spores, some foods especially nuts and proteinous foods, insect venoms, drugs (e.g. penicillin and sulphonamides), pollen grains from plants or flowers and dust particles are some examples of allergens that could provoke anaphylactic reactions in human or animal hosts. The clinical outcome or symptoms of Type I hypersensitivity reaction is usually affected by some host factors and other environmental conditions including but not limited to the amount of the administered allergen, route of administration and the number of times the host is exposed to the antigen or allergen. Type I hypersensitivity reaction could be prevented especially by avoiding contact with the allergen(s) responsible for the anaphylactic reaction. Anti-histamine drugs which block the release of histamine; and other clinical remedy could also be applied in containing the adverse effects of anaphylactic reactions in affected human hosts. In life-threatening cases, it is also critical to ensure appropriate airflow in the affected individual in order to maintain proper respiratory function of the affected human host.


Abbas A.K, Lichtman A.H and Pillai S (2010). Cellular and Molecular Immunology. Sixth edition. Saunders Elsevier Inc, USA.

Actor J (2014). Introductory Immunology. First edition. Academic Press, USA.

Alberts B, Bray D, Johnson A, Lewis J, Raff M, Roberts K and Walter P (1998). Essential Cell Biology: An Introduction to the Molecular Biology of the Cell. Third edition. Garland Publishing Inc., New York.

Bach F and Sachs D (1987). Transplantation immunology. N. Engl. J. Med. 317(8):402-409.

Barrett   J.T (1998).  Microbiology and Immunology Concepts.  Philadelphia,   PA:  Lippincott-Raven Publishers. USA.

Jaypal V (2007). Fundamentals of Medical Immunology. First edition. Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, India.

John T.J and Samuel R (2000). Herd Immunity and Herd Effect: New Insights and Definitions. European Journal of Epidemiology, 16:601-606.

Levinson W (2010). Review of Medical Microbiology and Immunology. Twelfth edition. The McGraw-Hill Companies, USA.

Roitt I, Brostoff J and Male D (2001). Immunology. Sixth edition. Harcourt Publishers Limited, Spain.

Zon LI (1995). Developmental biology of hematopoiesis. Blood, 86(8): 2876–91.

About the author


Leave a Comment